A cost-utility analysis of nivolumab in combination with ipilimumab compared to nivolumab monotherapy for advanced malignant melanoma in Norway
Melanoma is one of the most incident cancer types in Norway and the incidence rates have been increasing tremendously. Immunotherapies have been available yet no cost-effectiveness (CE) studies directly comparing different immune checkpoint inhibitors (ICIs) in this setting.The objective of this study is to evaluate the CE of ICI nivolumab in combination with ipilimumab for treatment of adult patients with advanced malignant melanoma compared to nivolumab monotherapy in the Norwegian healthcare setting, assuming a willingness-to-pay (WTP) of €55 850 per QALY.